Skip to content

Study · Randomized controlled trial · n = 117 · 2013

12 results

Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease.

Fan H, Pan Q, Xu Y, Yang X

Arquivos brasileiros de endocrinologia e metabologia1 Dec 2013Cited by 102 (Europe PMC)

PMID24402015 (opens in a new tab)DOI10.1590/s0004-27302013000900005 (opens in a new tab)PepBankPUB-24402015
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM and NAFLD, BMI was lower with exenatide than metformin after both groups improved.

    In plain wordsIn patients with diabetes and fatty liver, BMI was lower with exenatide than metformin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBMI
    Study

    n = 117

    Comparator
    Metformin
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    BMI, waist-to-hip ratio, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were markedly lower, and AST/ALT ratio and adiponectin in the exenatide group were dramatically higher than in the metformin group.
    3 context sentences
    Summary · context
    After 12 weeks of treatment, body weight, body mass index (BMI), waist-to-hip ratio, HbA1c, FPG, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were significantly reduced, and the AST/ALT ratio and adiponectin were markedly increased in both groups.
    Summary · context
    One hundred and seventeen patients with T2DM and NAFLD were randomly divided into exenatide group and metformin group.
    Summary · context
    Patients were treated with exenatide and metformin, respectively, for 12 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM and NAFLD, waist-to-hip ratio was lower with exenatide than metformin after both groups improved.

    In plain wordsIn patients with diabetes and fatty liver, waist-to-hip ratio was lower with exenatide than metformin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseWaist-to-hip ratio
    Study

    n = 117

    Comparator
    Metformin
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    BMI, waist-to-hip ratio, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were markedly lower, and AST/ALT ratio and adiponectin in the exenatide group were dramatically higher than in the metformin group.
    3 context sentences
    Summary · context
    After 12 weeks of treatment, body weight, body mass index (BMI), waist-to-hip ratio, HbA1c, FPG, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were significantly reduced, and the AST/ALT ratio and adiponectin were markedly increased in both groups.
    Summary · context
    One hundred and seventeen patients with T2DM and NAFLD were randomly divided into exenatide group and metformin group.
    Summary · context
    Patients were treated with exenatide and metformin, respectively, for 12 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM and NAFLD, postprandial glucose was lower with exenatide than metformin after both groups improved.

    In plain wordsIn patients with diabetes and fatty liver, glucose after meals was lower with exenatide than metformin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Decrease2-h PPG
    Study

    n = 117

    Comparator
    Metformin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    BMI, waist-to-hip ratio, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were markedly lower, and AST/ALT ratio and adiponectin in the exenatide group were dramatically higher than in the metformin group.
    3 context sentences
    Summary · context
    After 12 weeks of treatment, body weight, body mass index (BMI), waist-to-hip ratio, HbA1c, FPG, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were significantly reduced, and the AST/ALT ratio and adiponectin were markedly increased in both groups.
    Summary · context
    One hundred and seventeen patients with T2DM and NAFLD were randomly divided into exenatide group and metformin group.
    Summary · context
    Patients were treated with exenatide and metformin, respectively, for 12 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM and NAFLD, ALT was lower with exenatide than metformin after both groups improved.

    In plain wordsIn patients with diabetes and fatty liver, ALT was lower with exenatide than metformin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseALT
    Study

    n = 117

    Comparator
    Metformin
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    BMI, waist-to-hip ratio, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were markedly lower, and AST/ALT ratio and adiponectin in the exenatide group were dramatically higher than in the metformin group.
    3 context sentences
    Summary · context
    After 12 weeks of treatment, body weight, body mass index (BMI), waist-to-hip ratio, HbA1c, FPG, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were significantly reduced, and the AST/ALT ratio and adiponectin were markedly increased in both groups.
    Summary · context
    One hundred and seventeen patients with T2DM and NAFLD were randomly divided into exenatide group and metformin group.
    Summary · context
    Patients were treated with exenatide and metformin, respectively, for 12 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM and NAFLD, AST was lower with exenatide than metformin after both groups improved.

    In plain wordsIn patients with diabetes and fatty liver, AST was lower with exenatide than metformin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseAST
    Study

    n = 117

    Comparator
    Metformin
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    BMI, waist-to-hip ratio, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were markedly lower, and AST/ALT ratio and adiponectin in the exenatide group were dramatically higher than in the metformin group.
    3 context sentences
    Summary · context
    After 12 weeks of treatment, body weight, body mass index (BMI), waist-to-hip ratio, HbA1c, FPG, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were significantly reduced, and the AST/ALT ratio and adiponectin were markedly increased in both groups.
    Summary · context
    One hundred and seventeen patients with T2DM and NAFLD were randomly divided into exenatide group and metformin group.
    Summary · context
    Patients were treated with exenatide and metformin, respectively, for 12 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM and NAFLD, gamma-GT was lower with exenatide than metformin after both groups improved.

    In plain wordsIn patients with diabetes and fatty liver, gamma-GT was lower with exenatide than metformin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGamma-GT
    Study

    n = 117

    Comparator
    Metformin
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    BMI, waist-to-hip ratio, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were markedly lower, and AST/ALT ratio and adiponectin in the exenatide group were dramatically higher than in the metformin group.
    3 context sentences
    Summary · context
    After 12 weeks of treatment, body weight, body mass index (BMI), waist-to-hip ratio, HbA1c, FPG, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were significantly reduced, and the AST/ALT ratio and adiponectin were markedly increased in both groups.
    Summary · context
    One hundred and seventeen patients with T2DM and NAFLD were randomly divided into exenatide group and metformin group.
    Summary · context
    Patients were treated with exenatide and metformin, respectively, for 12 weeks.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM and NAFLD, hs-CRP was lower with exenatide than metformin after both groups improved.

    In plain wordsIn patients with diabetes and fatty liver, hs-CRP was lower with exenatide than metformin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Decreasehs-CRP
    Study

    n = 117

    Comparator
    Metformin
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    BMI, waist-to-hip ratio, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were markedly lower, and AST/ALT ratio and adiponectin in the exenatide group were dramatically higher than in the metformin group.
    3 context sentences
    Summary · context
    After 12 weeks of treatment, body weight, body mass index (BMI), waist-to-hip ratio, HbA1c, FPG, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were significantly reduced, and the AST/ALT ratio and adiponectin were markedly increased in both groups.
    Summary · context
    One hundred and seventeen patients with T2DM and NAFLD were randomly divided into exenatide group and metformin group.
    Summary · context
    Patients were treated with exenatide and metformin, respectively, for 12 weeks.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM and NAFLD, AST/ALT ratio was higher with exenatide than metformin after increases in both groups.

    In plain wordsIn patients with diabetes and fatty liver, AST/ALT ratio was higher with exenatide than metformin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseAST/ALT ratio
    Study

    n = 117

    Comparator
    Metformin
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    BMI, waist-to-hip ratio, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were markedly lower, and AST/ALT ratio and adiponectin in the exenatide group were dramatically higher than in the metformin group.
    3 context sentences
    Summary · context
    After 12 weeks of treatment, body weight, body mass index (BMI), waist-to-hip ratio, HbA1c, FPG, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were significantly reduced, and the AST/ALT ratio and adiponectin were markedly increased in both groups.
    Summary · context
    One hundred and seventeen patients with T2DM and NAFLD were randomly divided into exenatide group and metformin group.
    Summary · context
    Patients were treated with exenatide and metformin, respectively, for 12 weeks.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM and NAFLD, adiponectin was higher with exenatide than metformin after increases in both groups.

    In plain wordsIn patients with diabetes and fatty liver, adiponectin was higher with exenatide than metformin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseAdiponectin
    Study

    n = 117

    Comparator
    Metformin
    Outcome group
    Blood biochemical markers · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    BMI, waist-to-hip ratio, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were markedly lower, and AST/ALT ratio and adiponectin in the exenatide group were dramatically higher than in the metformin group.
    3 context sentences
    Summary · context
    After 12 weeks of treatment, body weight, body mass index (BMI), waist-to-hip ratio, HbA1c, FPG, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were significantly reduced, and the AST/ALT ratio and adiponectin were markedly increased in both groups.
    Summary · context
    One hundred and seventeen patients with T2DM and NAFLD were randomly divided into exenatide group and metformin group.
    Summary · context
    Patients were treated with exenatide and metformin, respectively, for 12 weeks.

Studies that did not test the peptide alone3

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 10HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In patients with T2DM and NAFLD, body weight decreased in both exenatide and metformin groups.

    In plain wordsIn patients with diabetes and fatty liver, weight decreased in both treatment groups, including metformin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight change in both groups
    Study

    n = 117

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    After 12 weeks of treatment, body weight, body mass index (BMI), waist-to-hip ratio, HbA1c, FPG, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were significantly reduced, and the AST/ALT ratio and adiponectin were markedly increased in both groups.
    2 context sentences
    Summary · context
    One hundred and seventeen patients with T2DM and NAFLD were randomly divided into exenatide group and metformin group.
    Summary · context
    Patients were treated with exenatide and metformin, respectively, for 12 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 11HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In patients with T2DM and NAFLD, HbA1c decreased in both exenatide and metformin groups.

    In plain wordsIn patients with diabetes and fatty liver, HbA1c decreased in both treatment groups, including metformin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c change in both groups
    Study

    n = 117

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    After 12 weeks of treatment, body weight, body mass index (BMI), waist-to-hip ratio, HbA1c, FPG, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were significantly reduced, and the AST/ALT ratio and adiponectin were markedly increased in both groups.
    2 context sentences
    Summary · context
    One hundred and seventeen patients with T2DM and NAFLD were randomly divided into exenatide group and metformin group.
    Summary · context
    Patients were treated with exenatide and metformin, respectively, for 12 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 12HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In patients with T2DM and NAFLD, fasting glucose decreased in both exenatide and metformin groups.

    In plain wordsIn patients with diabetes and fatty liver, fasting glucose decreased in both treatment groups, including metformin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseFPG change in both groups
    Study

    n = 117

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    After 12 weeks of treatment, body weight, body mass index (BMI), waist-to-hip ratio, HbA1c, FPG, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were significantly reduced, and the AST/ALT ratio and adiponectin were markedly increased in both groups.
    2 context sentences
    Summary · context
    One hundred and seventeen patients with T2DM and NAFLD were randomly divided into exenatide group and metformin group.
    Summary · context
    Patients were treated with exenatide and metformin, respectively, for 12 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.